CHRISTOPHER BARAN: Open Payments
NPI 1689082695 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$538 in 29 payments from 11 companies in 2025. Trend: 2023 $1,056 · 2024 $677 · 2025 $538
Food & beverage: $538
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $140 |
| PFIZER INC. | 4 | $96 |
| ABBVIE INC. | 5 | $83 |
| Lilly USA, LLC | 3 | $58 |
| Novo Nordisk Inc | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Abbott Laboratories | 1 | $22 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
Products named: TRELEGY ELLIPTA, UBRELVY, MOUNJARO, ELIQUIS, PREVNAR 20, Ozempic, AREXVY, OPSUMIT.
Industry payments across OH — which companies pay providers there.
